BCRXBIOCRYST PHARMACEUTICALS INC
Biological Products, (no Diagnostic Substances)
- Revenue
- $875M
- 94% YoY
- Operating margin
- 39.0%
- 7008% YoY
- EBITDA
- $342M
- 26498% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.4×
- $143M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear132% of net incomeCash flow under 80% of net income
- Dilutive SBCClear10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $157M | $271M | $331M | $451M | $875M | 94% |
| Operating income | −$178M | −$148M | −$104M | −$3M | $341M | 13509% |
| Net income | −$184M | −$247M | −$227M | −$89M | $264M | 397% |
| Operating cash flow | −$142M | −$162M | −$95M | −$52M | $347M | 768% |
| Capex | $2M | $1M | $2M | $1M | $2M | 120% |
| Stock-based comp | $35M | $45M | $56M | $65M | $85M | 30% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $13M | $1M | 105 | 201 |
| FY2024 | $8M | $11M | 101 | 156 |
| FY2023 | $5M | −$4M | 80 | 144 |
| FY2022 | $7M | $4M | 154 | 139 |
| FY2021 | $7M | $17M | 186 | 124 |